Axoltis Pharma, a biotech company dedicated to developing novel therapeutic solutions for neurodegenerative diseases, today announces the closing of a Series A funding round worth €18 million ($20.9M), to be disbursed in two installments. The funding, which includes new and historic investors, will enable the company to pursue the development of NX210c, its lead drug candidate, currently in phase 2 clinical trials in patients with ALS (Amyotrophic Lateral Sclerosis), also known as Lou Gehrig’s disease..

Axoltis Pharma是一家致力于开发神经退行性疾病新型治疗方案的生物技术公司，今天宣布完成了一轮价值1800万欧元（2090万美元）的A轮融资，资金将分两期发放。这笔融资包括新投资者和原有投资者的资金，将使公司能够继续推进其主要候选药物NX210c的开发，该药物目前正处于针对肌萎缩侧索硬化症（ALS，又称卢·格里克病）患者的二期临床试验阶段。

FIDAT Ventures and Cenitz co-led this round with contributions from private investors, including citizens coalesced through an equity crowdfunding campaign on the Capital Cell platform, business angels and the Le Cercle de Chiron syndicate. Agile Capital Market, an investment bank specializing in healthcare, supported the company by presenting Axoltis to key investors..

FIDAT Ventures和Cenitz共同领投了这一轮，私人投资者也参与其中，包括通过Capital Cell平台的股权众筹活动集结的公民、商业天使以及Le Cercle de Chiron辛迪加。专注于医疗保健的投资银行Agile Capital Market通过将Axoltis引荐给主要投资者来支持该公司。

Legacy investors, including Norfoalk, the Fonds Régional Avenir Industrie Auvergne Rhône-Alpes (Auvergne Rhône-Alpes Regional Industry Future Fund), advised by UI Investment, FaDièse 3, Simba Santé 2 (Angelor) and several historic business angels, as well as the CEO of Axoltis, also participated in the round..

包括Norfoalk、由UI Investment顾问管理的奥弗涅-罗纳-阿尔卑斯大区区域产业未来基金（Fonds Régional Avenir Industrie Auvergne Rhône-Alpes）、FaDièse 3、Simba Santé 2（Angelor）以及数位历史悠久的商业天使投资人，还有Axoltis的首席执行官也参与了本轮融资。

“At a time when biotech funding remains particularly challenging, the success of this round demonstrates that investors believe in our strategy,” said Yann Godfrin, CEO of Axoltis Pharma. “I wish to extend my warmest thanks to the historic investors and newcomers for their trust, support and enthusiasm, and the enlightening discussions we held over the course of their thorough due diligence during the last few months.”.

“在生物技术资金仍然特别具有挑战性的时候，这一轮融资的成功表明投资者相信我们的战略，”Axoltis Pharma首席执行官Yann Godfrin表示。“我要向一直以来的投资者和新加入的投资者致以最诚挚的感谢，感谢他们的信任、支持和热情，以及过去几个月在他们进行详尽尽职调查过程中我们所进行的富有启发性的讨论。”

The €18 million has been raised across two tranches, the second being contingent on results from the ‘SEALS’ phase 2 clinical trial currently underway. Launched at the end of 2024, SEALS aims to evaluate the efficacy and tolerability of NX210c in 82 patients with ALS, across 16 investigation sites. The trial also measures how the drug candidate helps repair the blood-brain barrier, which becomes damaged in many neurodegenerative disorders such as ALS, Alzheimer’s disease, multiple sclerosis and Parkinson’s disease.

这笔1800万欧元的资金分两批筹集，第二批资金的到位取决于目前正在开展的“SEALS”二期临床试验的结果。SEALS于2024年底启动，旨在评估NX210c在16个试验点对82名ALS患者的疗效和耐受性。该试验还测量了这种候选药物如何帮助修复在许多神经退行性疾病（如ALS、阿尔茨海默病、多发性硬化症和帕金森病）中受损的血脑屏障。

The last patient was enrolled in mid-November. Results are expected in Q2 2026..

最后一名患者于11月中旬入组。预计结果将于2026年第二季度公布。

ALS is one of the most common neuromuscular diseases in the world, with approximately 400,000 cases. It mainly attacks motor neurons, the nerve cells that transmit signals from the brain to the muscles and enable movement. The progressive destruction of these neurons leads to increasing muscle weakness, loss of mobility and speech, and in advanced stages, paralysis and breathing difficulties.

ALS是世界上最常见的神经肌肉疾病之一，大约有40万例。它主要攻击运动神经元，即那些将信号从大脑传递到肌肉并控制运动的神经细胞。这些神经元的逐渐破坏会导致肌肉无力加剧、行动和语言能力丧失，并在晚期出现瘫痪和呼吸困难。

Most patients die within two to five years. 90% of cases are sporadic, with no identified risk factors, and there is currently no cure for ALS..

大多数患者在两到五年内去世。90%的病例是散发性的，没有明确的风险因素，而且目前ALS尚无治愈方法。

The funds obtained will also help the company pursue research into other neurological indications where the properties of NX210c could deliver a significant impact, notably in repairing the blood-brain barrier.

获得的资金还将帮助该公司推进对其他神经系统适应症的研究，特别是NX210c的特性可能在修复血脑屏障方面产生重大影响的研究。

“The enthusiasm, perseverance and resilience demonstrated by the Axoltis team over the last few months are exceptional in the current financial climate,” said Dr Gilles Avenard, chairman of the Axoltis supervisory board.

“在当前的金融环境下，Axoltis团队在过去几个月中展现出的热情、毅力和韧性是异常突出的，”Axoltis监事会主席吉尔斯·阿韦纳德博士表示。

“Axoltis Pharma combines a high-performance team, a distinctive technology and remarkable development potential; we are delighted to be working alongside the company from now on,” said Frédéric Picq, co-founder and partner at Cenitz.

“Axoltis Pharma 拥有一支高效能团队、独特的技术和显著的发展潜力；我们很高兴从现在开始与该公司合作，”Cenitz 的联合创始人兼合伙人 Frédéric Picq 表示。

“Axoltis is developing a breakthrough treatment that could change the lives of millions of patients. If it reaches its full potential, hundreds of investors would also reap significant financial benefits. This translates into a win-win situation for society as a whole,” said Daniel Oliver Uriel, founder and CEO of Capital Cell..

“Axoltis 正在开发一种突破性的治疗方法，可能会改变数百万患者的生活。如果它能够充分发挥潜力，成百上千的投资者也将获得显著的经济回报。这对整个社会来说是一个双赢的局面，”Capital Cell 的创始人兼首席执行官丹尼尔·奥利弗·乌里尔表示。

“This fundraising allows us to maintain our head start in the clinical development of a product that restores the blood-brain barrier. It also means we can continue our discussions with world-class pharmaceutical companies, with a view to a global partnership that would help provide patients with quicker access to this treatment,” added Dr Yann Godfrin. .

“这次融资使我们能够在恢复血脑屏障的产品的临床开发中保持领先地位。这也意味着我们可以继续与世界级制药公司进行讨论，旨在达成全球合作伙伴关系，帮助患者更快获得这种治疗，”Yann Godfrin博士补充道。

Discussions will continue at the 44th annual J.P. Morgan Healthcare Conference to be held in San Francisco from January 12 to 14, 2026 – a must-attend event for healthcare industry operators. Axoltis Pharma has already confirmed that it will take part.

第44届摩根大通年度医疗保健会议将于2026年1月12日至14日在旧金山举行，届时讨论将继续进行——这是医疗行业从业者的必参加的活动。Axoltis Pharma已经确认将参加会议。

About NX210c

关于NX210c

Axoltis is developing NX210c, a cyclic peptide of 12 amino acids designed from the most conserved and repeated sequence of SCO-spondin, a glycoprotein that plays a crucial role in the development of the central nervous system during embryogenesis. NX210c is a novel drug candidate for neurodegenerative or trauma-related disorders, with blood-brain barrier repair, neuroprotective and neurotransmission improvement properties.

Axoltis正在开发NX210c，这是一种由12个氨基酸组成的环肽，设计灵感来源于SCO-spondin中高度保守且重复的序列。SCO-spondin是一种糖蛋白，在胚胎发生期间对中枢神经系统的发育起着至关重要的作用。NX210c是一种新型的神经退行性或创伤相关疾病的候选药物，具有修复血脑屏障、神经保护和改善神经传递的特性。

NX210c is protected by seven patents fully owned by Axoltis Pharma, including the composition of matter, which is covered in several countries. The FDA and the EMA have granted Orphan Drug Designation for NX210c in ALS. In 2023, the safety data collected in a phase Ib multiple ascending dose study showed NX210c to be well-tolerated.

NX210c 受到 Axoltis Pharma 完全拥有的七项专利保护，包括物质组成，在多个国家获得覆盖。FDA 和 EMA 已授予 NX210c 在 ALS（肌萎缩侧索硬化症）中的孤儿药资格。2023 年，一项 Ib 期多剂量递增研究中收集的安全性数据显示 NX210c 具有良好的耐受性。

The findings of a phase 2 trial in ALS patients are expected in Q2 2026..

预计ALS患者的二期试验结果将在2026年第二季度公布。

https://www.axoltis.com/our-product/properties

https://www.axoltis.com/our-product/properties

About Axoltis Pharma

关于Axoltis制药公司

Axoltis Pharma, a French biopharma company, develops innovative drugs for neurodegenerative and neurotraumatic diseases with a high unmet medical need. Headquartered in Clermont-Ferrand with offices in Lyon, France, Axoltis has established several partnerships with internationally recognized academic and private labs to develop its lead product, NX210c.

法国生物制药公司Axoltis Pharma致力于开发针对神经退行性和神经创伤性疾病的创新药物，这些疾病具有高度未满足的医疗需求。Axoltis总部位于克莱蒙费朗，并在法国里昂设有办事处，已与多家国际知名的学术和私人实验室建立了合作关系，以开发其主导产品NX210c。

The team is highly experienced in drug development, especially for neurological applications..

该团队在药物开发方面经验丰富，尤其是在神经学应用领域。

www.axoltis.com

www.axoltis.com

About FIDAT Ventures

关于FIDAT Ventures

The FIDAT Ventures investment vehicle is owned by the Oddo family. Chaired by Philippe Oddo, the company invests in high-potential businesses involved in the healthcare sector and is supported by a world-class scientific board.

FIDAT Ventures 投资工具由奥多家族拥有。该公司由菲利普·奥多 (Philippe Oddo) 担任主席，投资于医疗保健领域的高潜力企业，并得到世界级科学委员会的支持。

About Cenitz

关于Cenitz

Cenitz is a healthcare-focused private equity club with 250 accredited investors. Since 2021, it has supported 12 businesses with commitments ranging from €500,000 to €3 million. Supported by stringent selection and the ability to move quickly, Cenitz engages with projects that address genuine public health issues..

Cenitz是一家专注于医疗保健的私募股权俱乐部，拥有250名认证投资者。自2021年以来，它已支持了12家企业，承诺投资金额从50万欧元到300万欧元不等。依托严格的选择标准和快速行动的能力，Cenitz参与解决真正公共卫生问题的项目。

www.cenitz.fr

www.cenitz.fr

About Capital Cell

关于首都细胞

Capital Cell is Europe’s leading alternative investment platform for the Life Sciences and Biotechnology sector. Founded in 2015 in the scientific ecosystem of Barcelona, it has since become one of the largest investors in biotech startups in Europe, always with the ambition to globally drive innovation in health and biotechnology.

Capital Cell 是欧洲领先的生命科学和生物技术领域的另类投资平台。公司于2015年在巴塞罗那的科学生态系统中成立，此后成为欧洲生物技术初创企业最大的投资者之一，始终致力于在全球范围内推动健康和生物技术领域的创新。

In the last ten years, Capital Cell has funded over 150 companies, driving over 140 million euros into biomedical innovation..

过去十年，Capital Cell资助了150多家公司，为生物医学创新注入了超过1.4亿欧元。

www.capitalcell.com

www.capitalcell.com

About Norfoalk

关于诺福克

Investment company Norfoalk is based in Lyon, France. Founded and led by Jean-Guillaume Lafay, its strategy involves taking stakes in innovative, disruptive businesses. Jean-Guillaume Lafay is a serial entrepreneur (former CEO and co-founder of Mablink Bioscience, acquired by Eli Lilly) who draws on his dual expertise in biotechnology and private equity to direct the company’s investments towards projects with high scientific and societal potential..

投资公司Norfoalk总部位于法国里昂。该公司由让-纪尧姆·拉法伊创立并领导，其战略涉及投资于创新且具有颠覆性的企业。让-纪尧姆·拉法伊是一位连续创业者（曾担任Mablink Bioscience的首席执行官和联合创始人，该公司被礼来收购），他凭借在生物技术和私募股权领域的双重专长，将公司的投资引向具有高科学和社会潜力的项目。

For more information, visit LinkedIn: Jean-Guillaume Lafay

有关更多信息，请访问 LinkedIn：Jean-Guillaume Lafay

About UI Investissement

关于UI投资

UI is an independent company specializing in business development. For over 50 years, UI has been committed to working alongside managers of start-ups, SMEs and ETIs to create and develop economically and sustainably successful companies.

UI是一家独立的公司，专注于业务发展。50多年来，UI一直致力于与初创企业、中小型企业及中型企业的管理者携手合作，创建并发展经济上可持续成功的公司。

UI Investissement manages more than 1.7 billion euros in assets and invests with over 300 managers in business sectors essential to society, such as healthcare, agri-business, industry and services.

UI Investissement管理着超过17亿欧元的资产，并在医疗保健、农业综合企业、工业和服务等对社会至关重要的行业，与300多位经理人进行投资合作。

Founded in November 2023 by the Auvergne-Rhône-Alpes regional authority, the aim of the Auvergne-Rhône-Alpes Regional Future Industry Fund (FRAI – AURA) is to contribute to financing innovative seed- or scaleup- stage startups and mature businesses in the growth stage located in the Auvergne-Rhône-Alpes region. .

2023年11月由奥弗涅-罗纳-阿尔卑斯大区成立，奥弗涅-罗纳-阿尔卑斯大区未来工业基金（FRAI – AURA）的目标是为位于该地区的创新型种子阶段、成长阶段的初创企业或成熟企业提供融资支持。

www.ui-investissement.fr

www.ui-investissement.fr

About FaDièse

关于FaDièse

The FaDièse funds are entrepreneur funds worth €32 million overall. They involve around 70 associates – business leaders – who are supported by institutional investors including reinsurer SCOR and France’s public sector investment bank, Bpifrance.

FaDièse基金是总价值达3200万欧元的企业家基金。它们汇集了约70位合伙人——企业领导者，并得到包括再保险公司SCOR和法国公共投资银行Bpifrance在内的机构投资者的支持。

FaDièse’s success is based on an original approach combining the philosophy of business angels and the demands of venture capital. It combines support from experienced leaders who share strong values and build on successful entrepreneur-to-entrepreneur relationships, with an investment framework that meets professional standards in line with a long-term strategy, starting right from seed stage..

FaDièse的成功基于一种结合了商业天使哲学和风险投资要求的原创方法。它将经验丰富、价值观一致的领导者提供的支持，与建立在成功企业家之间关系基础上的框架相结合，同时采用符合长期战略的专业投资标准，从种子阶段就开始实施。

Since the first fund was created in 2001, FaDièse has already committed more than €28 million of funding to 50 companies working across the internet, electronics, life sciences and industrial sectors, and employing more than 250 people directly.

自2001年第一只基金成立以来，FaDièse已经向50家横跨互联网、电子、生命科学和工业领域的公司承诺了超过2800万欧元的资金支持，这些公司直接雇用了250多人。

For more information, visit LinkedIn: FaDiese

有关更多信息，请访问 LinkedIn: FaDiese

About Angelor

关于安吉洛尔

Based in Lyon, France, Angelor is an investment management company accredited by the Autorité des Marchés Financiers(French financial markets authority) in September 2022. Founded in 2008, Angelor is an independent venture capital company, with a mission to “develop finance that serves the common good”.

总部位于法国里昂的安吉洛（Angelor）是一家投资管理公司，于2022年9月获得法国金融市场管理局（Autorité des Marchés Financiers）认证。安吉洛成立于2008年，是一家独立的风险投资公司，其使命是“发展服务于公共利益的金融”。

Today, recognized for the quality of its shareholder base and the companies it finances, Angelor has federated numerous shareholders, most of whom are experienced business leaders committed to financing and supporting innovative entrepreneurs in their sector. Angelor has invested more than €33 million in 84 start-ups, particularly in the healthcare, agri-food and environment sectors – helping to create over 700 direct jobs, mainly in the Auvergne-Rhône-Alpes region..

如今，凭借其股东基础的质量和所投资公司的认可度，Angelor已联合了众多股东，其中大多数是经验丰富的商业领袖，致力于为其领域的创新企业家提供资金和支持。Angelor已在84家初创企业中投资超过3300万欧元，特别是在医疗保健、农食和环境领域，帮助创造了700多个直接就业机会，主要集中在奥弗涅-罗纳-阿尔卑斯地区。

www.angelor.fr

www.angelor.fr

About Le Cercle de Chiron

关于勒塞尔克勒德希隆

Le Cercle de Chiron is a network of business angels investing in life sciences companies. Its investments generally range from €150,000 to €300,000, with the possibility of co-investing in seed or Series A funding rounds alongside selected venture capital funds.

半人马座圆环是一个投资于生命科学公司的商业天使网络。其投资通常在15万欧元至30万欧元之间，并有可能与选定的风险投资基金共同参与种子轮或A轮融资。

For more information, visit LinkedIn: Le Cercle de Chiron

有关更多信息，请访问 LinkedIn：Le Cercle de Chiron